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Background: Rheumatic heart disease (RHD) was found in the THESUS-HF registry to be the third most
common cause of acute heart failure (AHF) in Sub-Saharan Africa.
Methods: One thousand six patients with AHF from 9 Sub-Saharan African countries were recruited in
THESUS-HF, of which 143 (14.3%) had RHD-AHF. Clinical characteristics and outcomes in patients with
RHD-AHF and non-RHD-AHF were compared. Kaplan-Meier plots for time to all-cause death and/or
HF readmission according to the presence of RHD-AHF and non-RHD-AHF were performed and survival
distributions compared using the log-rank test. Cox regression was used to determine the hazard ratio of
death to day 180 and death or readmission to day 60 after adjusting for confounders.
Results: Patients with RHD-AHF were younger, more often females, had higher rates of atrial fibrillation,
had less hypertension, hyperlipidemia and diabetes, had lower BP, and higher pulse rate and better kidney
function and echocardiographic higher ejection fraction larger left atria and more diastolic dysfunction.
Patients with RHD-AHF had a numerically longer mean stay in the hospital (10.5 vs. 8.8 days) and
significantly higher initial hospitalization mortality (9.1% vs. 3.4%).
Conclusions: In conclusion, patients with HF related to RHD were younger, have higher rate of atrial
fibrillation and have a worse short-term outcome compared to HF related to other etiologies in Sub-Saharan
Africa.
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Introduction
Heart failure (HF) is a major cause of morbidity and
mortality in developed and developing countries. Rheumatic
heart disease (RHD) is the third leading cause of HF in
Africa after hypertension and dilated cardiomyopathies as
reported in a recent systematic review and meta-analysis (1).
It was also the third most common HF etiology in the
multinational sub-Saharan Africa Survey of Heart Failure
(THESUS-HF) study (2). RHD diagnosis in Sub-Saharan
Africa (SSA) is usually made at an advanced stage of the
disease, when severe valve lesions become symptomatic,
and there is need for invasive intervention (3). Severe RHD
is lethal in the absence of invasive treatment. However,
interventions such as percutaneous mitral dilatation, closed
heart mitral commissurotomy and open-heart surgery can
be performed at only a few centers in Africa and are not
usually affordable (4). Given the high prevalence of RHF
and the high incidence of RHD-AHF in Africa, the current
analysis was performed to compare the socio-demographic,
clinical characteristics and outcome between patients
admitted with acute heart failure (AHF) due to RHD
and non-RHD (RHD-AHF and non-RHD-AHF) and
followed during 6 months using data from the multinational
THESUS-HF study. We present the protocol in accordance
with the STROBE reporting checklist (available at https://
dx.doi.org/10.21037/cdt-21-112).
Methods
THESUS-HF was a prospective, multicenter, observational
study of patients admitted between July 2007 and June
2010 for AHF in 12 hospitals from nine countries in
southern, eastern, central, and western sub-Saharan Africa,
mostly in Nigeria, Uganda, and South Africa. Eligibility
criteria included dyspnoea as the main complaint leading
to admission and symptoms and signs of congestive
heart failure including rales, oedema, and raised jugular
venous pulse. Echocardiographic findings supported
the diagnosis which a cardiologist confirmed. Patients’
written informed consent was required for entry into the
study. Each participating institution’s ethics committee
approved the study, which conformed to the principles of
the Declaration of Helsinki.. Investigators recorded data
onto standardized case report forms, and data collected
included medical history, medication use, laboratory
values, and physical examination with heart failure signs
and symptoms. Echocardiographic assessments were made
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locally and electrocardiograms were read centrally. Tests
for human immunodeficiency virus were done if clinically
indicated. The occurrence of readmissions and/or death
over 6 months was assessed either at clinic visits or through
telephone contacts.
Statistical analysis
Nine patients where the diagnosis of RHD was not available
were excluded from all analyses. Results are presented
as counts and percentages for categorical variables and
means, standard deviation (SD), median and 25th–75th
percentiles for continuous variables. Comparison between
participants with RHD-HF and those with non RHDHF for demographics, baseline clinical characteristics,
medical history, echocardiographic parameters, and
baseline medication use were tested using chi square tests
for qualitative variables, Wilcoxon rank-sum for ordinal
variables, and t-test for quantitative variables.
The associations between RHD-AHF or non-RHDAHF clinical outcomes were examined. A t-test was used
for comparing length of initial hospital stay between
groups. In-hospital mortality was compared between groups
using a logistic regression model with the odds ratio, 95%
confidence interval, and Wald chi-square P value presented.
For time-to-event outcomes, Kaplan-Meier estimates
are presented with the log rank test used for comparison
between groups; hazard ratios and 95% confidence intervals
from Cox regression models are also given. Hazard ratios
adjusting for predictors found to be associated with
readmission or death to day 60 and all-cause death to day
180 are also presented (5). These predictors include history
of hyperlipidemia, malignancy, and cor pulmonale and;
baseline rales, ejection fraction, BUN, and systolic BP for
death or readmission to Day 60 and history of malignancy,
cor pulmonale, and HIV; gender, smoking status, and
baseline values for systolic BP, creatinine, hemoglobin,
heart rate, orthopnea, rales, and edema for death to day
180. Multiple imputation methods were used to account
for missing predictors in the adjusted analyses. Rubin’s
algorithm (SAS PROC MIANALYZE) was used to average
parameter estimates across seven imputation datasets. Plots
of Kaplan-Meier curves for time to all-cause death and/or
HF readmission according to the presence of RHD-HF and
non-RHD-HF are shown. Data were analyzed using SAS
software version 9.4 (SAS Institute, Cary, NC, USA). A P
value <0.05 was considered statistically significant.
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with RHD-HF had significantly higher left atrial size (54.6
vs. 46 mm), lower LV end systolic diameter and higher
ejection fraction and higher mitral inflow variables such as
e wave deceleration time. The mean left ventricular endsystolic diameter was lower in RHD-HF patients.

Patients with acute heart failure
(AHF) (n=1,006)

Excluded (n=9)
• Diagnosis of RHD
not available (n=9)

Comparison of oral medications at baseline
The oral medication use is shown in Table 4. Patients with
RHD-HF were significantly more likely to be prescribed
beta-blockers (28.9% vs. 14.4%), however, the prescription
of beta blockers in patients with RHD-HF was not
influenced by the presence of atrial fibrillation. At admission
28.3% of patients with RHD-HF who were in atrial
fibrillation received beta blockers versus 29.1% of those
who were not in atrial fibrillation. Patients with RHD-HF
were less likely to be prescribed the RAAS blockers (54.3%
vs. 77%). The pattern of prescription of other medications
was similar in both groups.

lncluded in Analysis (n=997)

RHD-AHF (n=143)
(14.3%)

Non RHD-AHF (n=854)
(85.7%)

Figure 1 Analysis flow chart.

Results
Socio-demographic and risk factor profile
One thousand six (1,006) patients with AHF from nine
sub-Saharan African countries were recruited in THESUSHF, of which 997 were included in this analysis. There
were 143 patients (14.3%) with RHD-AHF (Figure 1).
Comparison of socio-demographic and risk factor profile is
shown in Table 1. Most of the patients were black Africans
(99%). The mean age (SD) was 52.3 (18.3) years, and 489
(49.1%) were males. Patients with heart failure associated
with RHD were younger (42.5 vs. 54.0 years), were more
likely to be females, and were more likely to have atrial
fibrillation (42.9% vs. 14.5%). Patients with non-RHDAHF had higher rates of hypertension, diabetes mellitus,
and hypercholesterolemia. In laboratory examinations they
had worst kidney function and higher glucose, but less
leukocytosis.

Comparison of clinical outcomes
The clinical outcomes (length of hospital stay, readmission
and death) are shown in Table 5. Length of initial stay was
available for 863 (86.6%) of the 997 patients; length of
stay was considered missing for 42 patients who died inhospital and 92 patients were missing the discharge date.
Patients with RHD-HF had a numerically, though nonsignificantly, longer length of initial stay in the hospital
(10.5 vs. 8.8 days) but had significantly higher initial
hospitalization mortality (9.1% vs. 3.4%). Readmission
at 60 days was comparable between groups (Figure 2A).
Patients with RHD-HF had a slightly higher estimated
rate of all-cause death or readmission through 60 days
(Figure 2B), although the difference was not statistically
significant. At 180 days, patients with RHD-HF had a
similar risk of death (Figure 2C).

Comparison of clinical and echocardiographic
characteristics

Discussion

Comparison of clinical presentation is shown in Table 2.
Patients with heart failure associated with RHD had
significantly lower systolic (118 vs. 132.4 mmHg) and
diastolic (76.2 vs. 85.7 mmHg) blood pressures, lower
severity of peripheral oedema and a higher mean ejection
fraction (48.1% vs. 38.1%). The mean eGFR and WBC
were significantly higher in patients with RHD-HF. The
echocardiographic evaluation is shown in Table 3. Patients

The etiology, medical management, and short-term
clinical outcomes of 1,006 Africans with AHF from nine
SSA countries were described in the sub-Saharan Africa
Survey of Heart Failure (THESUS-HF) (2). In this study,
RHD was the third most common cause of heart failure
in SSA. RHD has virtually disappeared in high income
countries but prevails as a major cause of cardiovascular
death and disability in children and young adults in low-
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Table 1 Comparison of sociodemographic and risk factor profile
Overall (N=997)

RHD-HF group (N=143)

Non-RHD-HF group (N=854)

P value#

Cameroon

90 (9.0)

10 (7.0)

80 (9.4)

<0.0001

Ethiopia

10 (1.0)

1 (0.7)

9 (1.1)

Kenya

32 (3.2)

1 (0.7)

31 (3.6)

Mozambique

76 (7.6)

8 (5.6)

68 (8.0)

Nigeria

422 (42.3)

29 (20.3)

393 (46.0)

Senegal

15 (1.5)

3 (2.1)

12 (1.4)

129 (12.9)

40 (28.0)

89 (10.4)

71 (7.1)

15 (10.5)

56 (6.6)

152 (15.2)

36 (25.2)

116 (13.6)

52.3 (18.28)

42.5 (17.10)

54.0 (17.96)

55.0 (39.0, 67.0)

42.5 (26.0, 55.0)

56.0 (41.0, 69.0)

Male sex, n (%)

489 (49.1)

54 (37.8)

435 (51.0)

0.0034

Black African, n (%)

980 (99.0)

141 (98.6)

839 (99.1)

0.6155

Atrial fibrillation, n (%)

183 (18.5)

60 (42.9)

123 (14.5)

<0.0001

0.4 (0.78)

0.5 (0.79)

0.4 (0.77)

0.1363

0.0 (0.0, 0.0)

0.0 (0.0, 1.0)

0.0 (0.0, 0.0)

Hyperlipidemia

90 (9.2)

6 (4.3)

84 (10.1)

0.0269

Smoking

97 (9.8)

11 (7.7)

86 (10.1)

0.3661

Hypertension

551 (55.5)

40 (28.0)

511 (60.1)

<0.0001

Diabetes

113 (11.4)

3 (2.1)

110 (12.9)

0.0002

Malignancy

13 (1.3)

1 (0.7)

12 (1.4)

0.4888

Cor pulmonale

72 (7.3)

9 (6.3)

63 (7.5)

0.6161

24.9 (5.82)

24.3 (6.75)

24.9 (5.65)

0.2341

23.3 (20.1, 27.1)

24.1 (20.9, 28.1)

Variables
Country, n (%)

South Africa
Sudan
Uganda
Age, years
Mean (SD)
Median (Q1, Q3)

<0.0001

No. of AHF admission in prior 12 months
Mean (SD)
Median (Q1, Q3)
Past history, n (%)

Body mass index
Mean (SD)
Median (Q1, Q3)

23.9 (20.9, 28.0)

P value from t-test for continuous variables or from χ -test for categorical variables. RHD, rheumatic heart disease; SD, standard
deviation; Q1, first quartile; Q3, third quartile.
#

2

and middle-income countries, including SSA (6-8). The
aim of this study was to compare the socio-demographic
and risk factor profile, clinical characteristics, and outcomes
between patients with RHD heart failure and Non-RHD
heart failure in SSA using data from the THESUS heart
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failure registry (2). These analyses showed that patients
with HF associated with RHD were: younger, more were
females, were more likely to be in atrial fibrillation, had less
hypertension, hyperlipidemia and diabetes, had lower BP,
and higher pulse rate and better kidney function but more
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Table 2 Comparison of clinical presentation
Overall (N=997)

RHD-HF group (N=143)

Non-RHD-HF group (N=854)

P value#

I

118 (17.9)

17 (15.2)

101 (18.4)

0.5741

II

302 (45.7)

60 (53.6)

242 (44.1)

III

213 (32.2)

31 (27.7)

182 (33.2)

IV

28 (4.2)

4 (3.6)

24 (4.4)

130.4 (33.54)

118.0 (24.70)

132.4 (34.38)

127.0 (106.0, 150.0)

111.0 (100.0, 130.0)

130.0 (110.0, 151.0)

84.4 (20.86)

76.2 (19.46)

85.7 (20.79)

80.0 (70.0, 100.0)

72.0 (62.0, 90.0)

83.5 (70.0, 100.0)

103.7 (21.58)

105.5 (26.39)

103.4 (20.66)

104.0 (90.0, 116.0)

102.0 (89.0, 120.0)

104.0 (90.0, 116.0)

0

154 (15.7)

22 (15.6)

132 (15.7)

1

166 (16.9)

30 (21.3)

136 (16.2)

2

355 (36.2)

60 (42.6)

295 (35.1)

3+

306 (31.2)

29 (20.6)

277 (33.0)

No rales

117 (13.4)

19 (17.9)

98 (12.8)

Rales <1/3

191 (21.9)

24 (22.6)

167 (21.8)

Rales 1/3–2/3

410 (47.1)

39 (36.8)

371 (48.5)

Rales >2/3

153 (17.6)

24 (22.6)

129 (16.9)

39.6 (16.35)

48.1 (14.88)

38.1 (16.15)

38.0 (27.0, 50.0)

47.3 (40.0, 58.0)

35.4 (25.2, 48.0)

1.4 (1.04)

1.2 (0.70)

1.4 (1.08)

1.1 (0.9, 1.5)

1.1 (0.9, 1.4)

1.1 (0.9, 1.5)

35.5 (32.95)

30.9 (24.89)

36.3 (34.09)

26.8 (16.8, 41.7)

22.1 (14.3, 40.0)

27.8 (17.2, 42.0)

Variables
NYHA Class, n (%)

Systolic BP, mmHg
Mean (SD)
Median (Q1, Q3)

<0.0001

Diastolic BP, mmHg
Mean (SD)
Median (Q1, Q3)

<0.0001

Heart rate, bpm
Mean (SD)
Median (Q1, Q3)

0.2709

Peripheral edema, n (%)
0.0291

Rales, n (%)
0.7000

Ejection fraction, %
Mean (SD)
Median (Q1, Q3)

<0.0001

Creatinine, mg/dL
Mean (SD)
Median (Q1, Q3)

0.0454

BUN, mg/dL
Mean (SD)
Median (Q1, Q3)

0.0772

Table 2 (continued)
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Table 2 (continued)
Variables

Overall (N=997)

RHD-HF group (N=143)

Non-RHD-HF group (N=854)

P value#

83.9 (47.53)

92.2 (59.73)

82.4 (44.93)

0.0239

77.1 (55.0, 103.8)

79.9 (62.1, 107.0)

76.8 (53.3, 103.5)

157.6 (54.25)

148.4 (41.57)

159.2 (56.07)

152.1 (124.0, 187.0)

152.1 (114.7, 171.6)

153.3 (124.8, 187.2)

106.3 (53.94)

98.2 (40.31)

107.7 (55.92)

97.9 (71.2, 124.6)

90.5 (67.3, 115.7)

97.9 (71.2, 127.3)

109.8 (49.85)

99.3 (44.16)

111.5 (50.55)

93.7 (84.0, 117.0)

91.8 (82.8, 101.7)

95.0 (84.6, 120.0)

12.2 (2.42)

12.0 (2.07)

12.2 (2.47)

12.3 (10.7, 13.7)

12.0 (10.5, 13.3)

12.3 (10.7, 13.8)

30.3 (13.37)

28.4 (13.16)

30.6 (13.39)

30.0 (20.0, 39.6)

29.0 (19.0, 36.5)

30.0 (20.4, 40.0)

135.1 (6.61)

135.1 (6.55)

135.1 (6.63)

135.3 (131.0, 139.0)

136.0 (131.5, 139.0)

135.0 (131.0, 139.2)

7,689.0 (4,101.53)

8,826.5 (5,542.82)

7,495.0 (3,772.01)

6,800.0 (5,200.0, 8,960.0)

7,200.0 (5,700.0, 9,900.0)

6,700.0 (5,090.0, 8,800.0)

eGFR, mL/min/1.73 m2
Mean (SD)
Median (Q1, Q3)
Cholesterol, mg/dL
Mean (SD)
Median (Q1, Q3)

0.0701

Triglycerides, mg/dL
Mean (SD)
Median (Q1, Q3)

0.1127

Glucose, mg/dL
Mean (SD)
Median (Q1, Q3)

0.0114

Hemoglobin, g/dL
Mean (SD)
Median (Q1, Q3)

0.4753

Lymphocytes, %
Mean (SD)
Median (Q1, Q3)

0.0986

Sodium, mmol/L
Mean (SD)
Median (Q1, Q3)

0.9192

WBC, No./µL
Mean (SD)
Median (Q1, Q3)

0.0004

P value from t-test for continuous variables, Wilcoxon rank-sum test for ordinal variables, and χ2-test for categorical variables. RHD,
rheumatic heart disease; SD, standard deviation; Q1, first quartile; Q3, third quartile; NYHA, New York Heart Association; BUN, blood urea
nitrogen; eGFR, estimated glomerular filtration rate; WBC, white blood cell.
#

leukocytosis. By echocardiography patients with RHDAHD had higher ejection fraction but larger left atria and
more diastolic dysfunction. The study also showed that
RHD-HF patients were significantly more often prescribed
beta blockers, had a significantly worse short-term outcome,
especially higher mortality on initial hospitalization.
However, the longer-term (60 and 180 days) outcomes did
not differ significantly in patients with RHD-HF. Some
of the differences observed between patients with RHDAHF and non-RHD AHF may be due to the fact that some
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specific subgroups of non-RHD AHF are more likely to
have specific characteristics, such as higher BP in patients
with hypertension related AHF. These differences cannot
be explored here in detail due to the limited number of
patients presenting with different AHF etiologies.
To our knowledge this is the first study comparing
patients with AHF associated with RHD to patients with
other etiologies of AHF not related to RHD in SSA.
Previous reports from SSA have shown that heart failure
affects men and women in the most productive years of their
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Table 3 Comparison of echocardiographic evaluations
Variables

Overall (N=997)

RHD-HF group (N=143)

Non-RHD-HF group (N=854)

P value#

94.8 (17.88)

98.5 (22.14)

94.1 (16.89)

0.0135

94.0 (84.0, 104.0)

98.0 (87.0, 110.0)

94.0 (84.0, 104.0)

46.1 (13.16)

41.8 (12.18)

46.8 (13.19)

47.0 (37.0, 55.0)

42.0 (32.0, 48.0)

48.0 (37.9, 56.0)

57.7 (11.59)

57.2 (12.20)

57.8 (11.49)

58.0 (50.0, 65.0)

58.0 (49.0, 64.0)

58.4 (50.1, 65.0)

11.2 (3.25)

11.3 (3.12)

11.2 (3.27)

11.0 (9.0, 13.0)

11.0 (9.0, 13.0)

11.0 (9.0, 13.0)

10.7 (2.88)

10.9 (2.63)

10.7 (2.92)

10.1 (9.0, 12.8)

10.6 (9.0, 12.0)

10.0 (9.0, 13.0)

47.1 (9.07)

54.6 (10.97)

46.0 (8.15)

47.0 (41.0, 52.4)

53.0 (47.0, 61.0)

46.0 (41.0, 51.0)

2,768.0 (928.15)

3,624.1 (1,147.45)

2,637.6 (816.06)

2,620.0 (2,200.0, 3,240.0)

3,410.0 (2,930.0, 4,220.0)

2,560.0 (2,103.0, 3,100.0)

54.3 (50.08)

87.0 (83.02)

49.8 (41.90)

47.6 (9.6, 88.0)

70.3 (12.0, 148.0)

47.0 (9.3, 82.0)

150.0 (92.93)

216.4 (199.44)

141.2 (62.43)

130.0 (100.0, 171.0)

162.5 (110.5, 224.5)

130.0 (100.0, 167.0)

36.5 (34.62)

55.7 (57.75)

34.7 (30.99)

30.0 (6.2, 55.0)

36.0 (6.2, 87.0)

29.5 (6.2, 54.0)

126.0 (44.99)

138.9 (78.77)

124.9 (40.51)

123.0 (100.0, 150.0)

121.0 (100.0, 155.0)

123.0 (100.0, 150.0)

Heart rate, bmp
Mean (SD)
Median (Q1, Q3)
Dimensions and LV function
LV systole size, mm
Mean (SD)
Median (Q1, Q3)

<0.0001

LV diastole size, mm
Mean (SD)
Median (Q1, Q3)

0.5757

IV septum (diastole), mm
Mean (SD)
Median (Q1, Q3)

0.7483

Posterior wall (diastole), mm
Mean (SD)
Median (Q1, Q3)

0.5293

Diastolic function
Left atrial planimetry size, mm
Mean (SD)
Median (Q1, Q3)

<0.0001

2

Left atrial planimetry size, mm
Mean (SD)
Median (Q1, Q3)

<0.0001

Mitral E wave, cm/s
Mean (SD)
Median (Q1, Q3)

<0.0001

E wave deceleration time, ms
Mean (SD)
Median (Q1, Q3)

<0.0001

Mitral A wave, cm/s
Mean (SD)
Median (Q1, Q3)

<0.0001

Mitral A wave duration time, ms
Mean (SD)
Median (Q1, Q3)

0.0472

#

P value from t-test. RHD, rheumatic heart disease; SD, standard deviation; Q1, first quartile; Q3, third quartile; LV, left ventricular; IV,
interventricular.
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Table 4 Comparison of prescribed oral medication use at admission
Variable, n (%)

RHD-HF group (N=143)

ACEi/ARBs

726 (73.8)

76 (54.3)

650 (77.0)

<0.0001

Loop diuretics

155 (16.0)

27 (19.3)

128 (15.5)

0.2561

Beta blockers

161 (16.5)

41 (28.9)

120 (14.4)

<0.0001

Digoxin

433 (44.3)

63 (44.1)

370 (44.4)

0.9453

Hydralazine

12 (1.2)

1 (0.7)

11 (1.3)

0.5380

Nitrates

50 (5.1)

8 (5.6)

42 (5.0)

0.7555

Aldosterone inhibitors

643 (65.7)

86 (60.6)

557 (66.5)

0.1649

Statins

100 (10.3)

14 (9.9)

86 (10.4)

0.8724

Aspirin

351 (35.8)

45 (31.7)

306 (36.5)

0.2674

Anticoagulants

337 (34.3)

53 (37.3)

284 (33.8)

0.4146

#

Non-RHD-HF group (N=854)

P value#

Overall (N=997)

P value from χ2-test. RHD, rheumatic heart disease; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

Table 5 Comparison of clinical outcomes
Variables

RHD-HF group Non-RHD-HF group
(N=143)
(N=854)

P value#

Unadjusted: OR/HR
(95% CI)1

Adjusted:
HR (95% CI)2

Length of initial hospital stay, days
Mean (SD)

10.5 (15.08)

8.8 (8.79)

Median (Q1, Q3)

7.0 (5.0, 9.0)

7.0 (5.0, 10.0)

Initial hospitalization mortality, n (%)

13 (9.1)

29 (3.4)

0.0017

2.84 (1.44, 5.61)

–

Readmission to day 60, n (KM %)

9 (8.2)

65 (9.3)

0.6604

0.86 (0.43, 1.72)

–

Death to day 60, n (KM %)

18 (13.5)

77 (10.2)

0.1591

1.44 (0.86, 2.41)

–

Death or readmission to day 60, n (KM %)

25 (19.2)

113 (15.1)

0.1605

1.36 (0.88, 2.10)

1.40 (0.88, 2.25)

Death to day 180, n (KM %)

25 (19.7)

126 (17.6)

0.3536

1.22 (0.80, 1.88)

1.10 (0.71, 1.70)

#

0.0684

2

P value from ANOVA (F-test) for length of initial stay, log-rank test for time-to event outcomes, and Wald-χ -from a logistic regression
model for in-hospital mortality. 1Odds ratio (95% CI) provided for in-hospital mortality outcome. 2Multiple imputations used adjusting for
the following predictors. Death to day 180: gender, history of malignancy, history of cor pulmonale, history of HIV, smoking status, and
baseline values for systolic BP, creatinine, hemoglobin, heart rate, orthopnea, rales, and edema. Death or readmission to day 60: history
of hyperlipidemia, history of malignancy, history of cor pulmonale, and baseline values for rales, ejection fraction, BUN, and systolic
BP. RHD, rheumatic heart disease; SD, standard deviation; Q1, first quartile; Q3, third quartile; KM, Kaplan-Meier; OR, odds ratio; HR,
hazard ratio.

lives with a mean age of 52 years (2). The characteristics
and outcomes of AHF related to RHD are not commonly
reported and this series addresses a significant knowledge
gap addressing RHD associated AHF. In this analysis,
patients with RHD-AHF were significantly younger with
a mean age of 42 years, compared to patients with other
heart failure etiologies. The mean admission blood pressure
was lower in patients with RHD-AHF probably because
hypertension was the main etiology of non RHD-AHF,

© Cardiovascular Diagnosis and Therapy. All rights reserved.

increasing this way the blood pressure in this group.
The prevalence of atrial fibrillation among patients with
RHD-AHF was 42% compared to 14.5% in non RHDAHF. Atrial fibrillation is one of the main complications of
RHD and its prevalence increases with severity of valvular
lesion. A study in Ethiopia reported a high prevalence of
atrial fibrillation in patients with RHD (46.8%) which is
comparable to that reported in this study (9). This was
however higher than that reported in the REMEDY study
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Figure 2 Kaplan-Meier survival plots for (A) all-cause readmission through day 60, (B) all-cause death or readmission through day 60, and (C)
all-cause death through day 180.

with a prevalence of atrial fibrillation of 21% (10). RHD
is associated with a large atrium. An enlarged atrium is
predictor of atrial fibrillation as shown by several studies
(11,12), a finding that was also observed in the current
analysis where patients had larger left atria. These findings
suggest that atrial fibrillation is more common in patients
with RHD admitted due to AHF then those with chronic,
more compensated RHD.
The prescription of beta blockers in patients with
heart failure in SSA is low (1,13). In this report, patients
with RHD-AHF were more likely to be prescribed beta
blockers. This could be explained by a higher prevalence of
atrial fibrillation with higher heart rates in these patients.
Mitral stenosis, being an indisputable indication for beta
blockers could also be a reason for this difference. Patients
with RHD-AHF were also less likely to be prescribed
angiotensin converting enzyme inhibitors which could be
related to the higher left ventricular ejection fraction.
Heart failure is a leading cause of morbidity and hospital
readmission (14). In the current analysis, patients with
RHD-AHF had higher initial hospitalization mortality,
and a trend toward higher initial hospital length of stay.

© Cardiovascular Diagnosis and Therapy. All rights reserved.

However, by 6 months follow up the outcomes of patients
with AHF were similar regardless of whether the AHF was
due to RHD or other causes. This information is addressing
an important knowledge gap regarding the course and
short-term outcomes of RHD related AHF.
Although we don’t know the number of patients with
RHD-AHF that underwent surgery, limited access to surgical
treatment can explain in part the higher risk of early adverse
outcome in patients with RHD-AHF in this analysis. RHD
is usually diagnosed late in Africa with patients presenting
late with advanced disease leading to high morbidity and
mortality (15). The REMEDY study demonstrated that
patients with RHD often present with moderate-to-severe
multivalvular disease (63.9%), heart failure (33.4%), and
pulmonary hypertension (28.8%); atrial fibrillation (21.8%),
stroke (7.1%), and infective endocarditis (4%) are also
seen (10). In this background of low- and middle-income
countries, prohibitive costs and limited access to surgical and
catheter-based interventions leave few options for treatment
of such late presentations (16). These factors can explain the
increased mortality and readmission in patients with heart
failure associated with RHD.
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Conclusions
This series is the first to report on the characteristics and
short-term outcomes of patients with RHD related AHF
in recent years. Our data suggest that patients with AHF
related to RHD are younger, have a higher prevalence of
atrial fibrillation and have a worse outcome during the
initial admission compared to heart failure related to other
etiologies in SSA, however by 6 months their outcomes are
similar to other patients with AHF not related to RHD.
Limitations
The current analysis of the THESUS-HF registry is posthoc. As such it is limited by the nature of the post-Hoc
analyses. Some of the comparisons described between
RHD-AHF patients and non-RHD-AHF patients may
be driven due to differences in specific subgroups of nonRHD-AHF such as hypertensive, HIV or postpartum
cardiomyopathy. More detailed analysis of such contrast
could not be performed due to the size of the subgroups
and hence small numbers of events in each group. Data on
the number of patients who underwent surgery for RHD
are not available in THESUS-HF. Data regarding the
type of valvular lesions in patients with RHD-HF is also
unavailable in this cohort. Despite these limitations, this
paper serves to highlight an important facet of a neglected
disease from the regions where it has the greatest impact in
terms of mortality and morbidity. Thus, there is need for
increased advocacy on RHD in SSA.
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